Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Solar ETF (TAN) vs TransMedics Group Inc (TMDX) Price & Performance

Invesco Solar ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Invesco Solar ETF vs TransMedics Group Inc — how do they compare? Invesco Solar ETF trades at $52.39, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Invesco Solar ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

TANTMDX
Sector
Sector/ThematicTechnology
52-Week High
$73.95$150.42
52-Week Low
$36.62$61.99
Market Cap
$3.10B
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Solar ETF

TAN (Invesco Solar ETF) trades at $52.33, up 0.91% with a bearish technical signal from moving averages. The solar ETF faces mixed sentiment as recent Trump administration tariffs on polysilicon imports provide potential tailwinds for U.S. solar manufacturers while regulatory uncertainty and high volatility (beta 1.41) persist. Technical indicators show neutral oscillators with key support at $50 and resistance at $53.

The solar sector outlook is bifurcated between policy-driven opportunities and fundamental challenges. Tariff protections could benefit domestic manufacturers, but high expense ratios (0.7%) and residential solar demand concerns create headwinds. Investment appeal depends on policy stability and the sector's ability to capitalize on growing energy demand from data centers and AI infrastructure.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About Invesco Solar ETF

TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.

Read more on TAN

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX